Randomized Controlled Trial of Web-Based Psychoeducation for Women With Borderline Personality Disorder

Overview

Journal J Clin Psychiatry

Specialty Psychiatry

Date 2017 Jul 14

PMID 28703950

Citations 23

Authors

Mary C Zanarini

Lindsey C Conkey

Christina M Temes

Garrett M Fitzmaurice

Affiliations

Soon will be listed here.

Abstract

Objective: To determine if internet-based psychoeducation for borderline personality disorder is effective in reducing symptom severity and improving psychosocial functioning.

Methods: Eighty women who met DSM-IV criteria for borderline personality disorder were randomly assigned either to the internet-based psychoeducation treatment group (n = 40) or to the internet-based control group with no psychoeducation (n = 40). Recruitment was conducted from July 2013 to March 2015. Subjects participated in 15 assessment periods that were divided into an acute phase (weeks 1-12) and a maintenance phase (months 6, 9, and 12). Main outcomes were assessed using the Zanarini Rating Scale for Borderline Personality Disorder.

Results: In the acute phase, women in the treatment group were found to have a significant decline in their scores on all 10 outcomes studied, while women in the control group had a significant decline on 7 of these outcomes. Two between-group differences were found to be significant-those in the treatment group reported a significantly greater decline in their impulsivity (z = -1.98, P = .048) and a significantly greater increase in their psychosocial functioning (z = -1.97, P = .049) than those in the control group. In the maintenance phase, those in the treatment group were found to have a significant decline in their scores on 9 of the 10 outcomes studied, while those in the control group had a significant decline in 3 of these outcomes. In terms of between-group differences, those in the treatment group reported a significantly greater decline in all 5 studied areas of borderline psychopathology: affective symptoms (z = -2.31, P = .021), cognitive symptoms (z = -3.20, P = .001), impulsivity (z = -2.44, P = .015), interpersonal difficulties (z = -2.15, P = .032), and overall borderline personality disorder symptoms (z = -2.11, P = .035).

Conclusions: Taken together, these results suggest that internet-based psychoeducation is an effective form of early treatment for reducing the symptom severity of borderline personality disorder for periods up to 1 year.

Trial Registration: ClinicalTrials.gov identifier: NCT01719731.

Citing Articles

Digital Interventions for Symptoms of Borderline Personality Disorder: Systematic Review and Meta-Analysis.

Lindsay J, McGowan N, Henning T, Harriss E, Saunders K J Med Internet Res. 2024; 26:e54941.

PMID: 39612494 PMC: 11645515. DOI: 10.2196/54941.

Physical Activity in young female outpatients with BORderline personality Disorder (PABORD): a study protocol for a randomized controlled trial (RCT).

de Girolamo G, Leone S, DAddazio M, Toffol E, Martinelli A, Bellini S Trials. 2024; 25(1):685.

PMID: 39415283 PMC: 11484461. DOI: 10.1186/s13063-024-08525-8.

Recovery-focused self-help intervention using vodcasts for patients with personality disorder: feasibility randomised controlled trial.

Kim Y, An Z, Han S, Ko J, Kwag K BJPsych Open. 2024; 10(1):e31.

PMID: 38229480 PMC: 10897696. DOI: 10.1192/bjo.2023.647.

Online psychoeducation and digital assessments as a first step of treatment for borderline personality disorder: A protocol for a pilot randomized controlled trial.

Choi-Kain L, Murray G, Jurist J, Ren B, Germine L PLoS One. 2023; 18(12):e0294331.

PMID: 38060545 PMC: 10703320. DOI: 10.1371/journal.pone.0294331.

Longitudinal Description and Prediction of Smoking Among Borderline Patients: An 18-Year Follow-Up Study.

Branas M, Frankenburg F, Temes C, Fitzmaurice G, Zanarini M J Clin Psychiatry. 2023; 84(6).

PMID: 37943989 PMC: 11671101. DOI: 10.4088/JCP.22m14756.

References

Salzman C, Wolfson A, Schatzberg A, Looper J, Henke R, Albanese M . Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995; 15(1):23-9. DOI: 10.1097/00004714-199502000-00005. View

Donker T, Griffiths K, Cuijpers P, Christensen H . Psychoeducation for depression, anxiety and psychological distress: a meta-analysis. BMC Med. 2009; 7:79. PMC: 2805686. DOI: 10.1186/1741-7015-7-79. View

Hollander E, Swann A, Coccaro E, Jiang P, Smith T . Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005; 162(3):621-4. DOI: 10.1176/appi.ajp.162.3.621. View

Zanarini M, Vujanovic A, Parachini E, Boulanger J, Frankenburg F, Hennen J . Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord. 2003; 17(3):233-42. DOI: 10.1521/pedi.17.3.233.22147. View

Rinne T, van den Brink W, Wouters L, van Dyck R . SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002; 159(12):2048-54. DOI: 10.1176/appi.ajp.159.12.2048. View

Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J . Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry. 2008; 165(4):468-78. PMC: 3608469. DOI: 10.1176/appi.ajp.2007.07071079. View

Zanarini M, Weingeroff J, Frankenburg F, Fitzmaurice G . Development of the self-report version of the Zanarini Rating Scale for Borderline Personality Disorder. Personal Ment Health. 2015; 9(4):243-9. PMC: 4609276. DOI: 10.1002/pmh.1302. View

Bender D, Dolan R, Skodol A, Sanislow C, Dyck I, McGlashan T . Treatment utilization by patients with personality disorders. Am J Psychiatry. 2001; 158(2):295-302. DOI: 10.1176/appi.ajp.158.2.295. View

Lequesne E, Hersh R . Disclosure of a diagnosis of borderline personality disorder. J Psychiatr Pract. 2004; 10(3):170-6. DOI: 10.1097/00131746-200405000-00005. View

10.

Zanarini M, Frankenburg F, Reich D, Fitzmaurice G . Attainment and stability of sustained symptomatic remission and recovery among patients with borderline personality disorder and axis II comparison subjects: a 16-year prospective follow-up study. Am J Psychiatry. 2012; 169(5):476-83. PMC: 3509999. DOI: 10.1176/appi.ajp.2011.11101550. View

11.

Nickel M, Nickel C, Kaplan P, Lahmann C, Muhlbacher M, Tritt K . Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005; 57(5):495-9. DOI: 10.1016/j.biopsych.2004.11.044. View

12.

Soler J, Pascual J, Campins J, Barrachina J, Puigdemont D, Alvarez E . Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005; 162(6):1221-4. DOI: 10.1176/appi.ajp.162.6.1221. View

13.

Paris J, Brown R, Nowlis D . Long-term follow-up of borderline patients in a general hospital. Compr Psychiatry. 1987; 28(6):530-5. DOI: 10.1016/0010-440x(87)90019-8. View

14.

Zanarini M, Frankenburg F . omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2002; 160(1):167-9. DOI: 10.1176/appi.ajp.160.1.167. View

15.

Zimmerman M, Chelminski I, Young D, Dalrymple K . A clinically useful anxiety outcome scale. J Clin Psychiatry. 2010; 71(5):534-42. DOI: 10.4088/JCP.09m05264blu. View

16.

Zanarini M, Frankenburg F . A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. J Pers Disord. 2008; 22(3):284-90. DOI: 10.1521/pedi.2008.22.3.284. View

17.

Tritt K, Nickel C, Lahmann C, Leiberich P, Rother W, Loew T . Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005; 19(3):287-91. DOI: 10.1177/0269881105051540. View

18.

Cowdry R, Gardner D . Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988; 45(2):111-9. DOI: 10.1001/archpsyc.1988.01800260015002. View

19.

Pfohl B, Blum N, St John D, McCormick B, Allen J, Black D . Reliability and validity of the Borderline Evaluation of Severity Over Time (BEST): a self-rated scale to measure severity and change in persons with borderline personality disorder. J Pers Disord. 2009; 23(3):281-93. PMC: 3608461. DOI: 10.1521/pedi.2009.23.3.281. View

20.

Bogenschutz M, Nurnberg H . Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004; 65(1):104-9. DOI: 10.4088/jcp.v65n0118. View